nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Absence of mutations of the histone methyltransferase gene EZH2 in splenic b-cell marginal zone lymphoma
|
Salido, Marta |
|
2011 |
35 |
3 |
p. e23-e24 nvt p. |
artikel |
2 |
Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2010
|
Malcovati, Luca |
|
2011 |
35 |
3 |
p. 291-294 4 p. |
artikel |
3 |
Aspirin in low-risk essential thrombocythemia, not so simple after all?
|
Harrison, Claire |
|
2011 |
35 |
3 |
p. 286-289 4 p. |
artikel |
4 |
BCR-ABL peptide vaccination in healthy subjects: Immunological responses are equivalent to those in chronic myeloid leukaemia patients
|
Rojas, José M. |
|
2011 |
35 |
3 |
p. 369-372 4 p. |
artikel |
5 |
Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism
|
Whittle, Annika M. |
|
2011 |
35 |
3 |
p. 419-421 3 p. |
artikel |
6 |
Conventional cytogenetics in chronic lymphocytic leukemia (CLL)
|
Krings Rocha, Cristiano |
|
2011 |
35 |
3 |
p. e25- 1 p. |
artikel |
7 |
Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/lymphoma
|
Beltran, Brady |
|
2011 |
35 |
3 |
p. 334-339 6 p. |
artikel |
8 |
Early assessment of treatment response in patients with AML using [18F]FLT PET imaging
|
Vanderhoek, Matt |
|
2011 |
35 |
3 |
p. 310-316 7 p. |
artikel |
9 |
Editorial Board
|
|
|
2011 |
35 |
3 |
p. CO2- 1 p. |
artikel |
10 |
Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome
|
Mavroudi, Irene |
|
2011 |
35 |
3 |
p. 323-328 6 p. |
artikel |
11 |
Erythropoietin activates telomerase through transcriptional and posttranscriptional regulation in human erythroleukemic JAS-REN-A cells
|
Akiyama, Masaharu |
|
2011 |
35 |
3 |
p. 416-418 3 p. |
artikel |
12 |
Evaluation of TET2 deletions in myeloid disorders: A fluorescence in situ hybridization analysis of 109 cases
|
Klaus, Mirjam |
|
2011 |
35 |
3 |
p. 413-415 3 p. |
artikel |
13 |
[FeIII(salophene)Cl], a potent iron salophene complex overcomes multiple drug resistance in lymphoma and leukemia cells
|
Lee, Soo-Young |
|
2011 |
35 |
3 |
p. 387-393 7 p. |
artikel |
14 |
Germline PTPN11 mutation affecting exon 8 in a case of syndromic juvenile myelomonocytic leukemia
|
Prontera, Paolo |
|
2011 |
35 |
3 |
p. e13-e14 nvt p. |
artikel |
15 |
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902
|
Stone, Richard M. |
|
2011 |
35 |
3 |
p. 329-333 5 p. |
artikel |
16 |
Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma
|
Gimeno, Eva |
|
2011 |
35 |
3 |
p. 358-362 5 p. |
artikel |
17 |
It takes two-to-leukemia: About addictions and requirements
|
Marschalek, Rolf |
|
2011 |
35 |
3 |
p. 424-425 2 p. |
artikel |
18 |
Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo
|
Qian, Zhengzi |
|
2011 |
35 |
3 |
p. 380-386 7 p. |
artikel |
19 |
Marked bone marrow hypoplasia associated with sorafenib-induced marrow blast clearance in two patients with FLT3-ITD acute myeloid leukemia
|
Fesler, Mark J. |
|
2011 |
35 |
3 |
p. e21-e22 nvt p. |
artikel |
20 |
Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features
|
Wang, Sa A. |
|
2011 |
35 |
3 |
p. 351-357 7 p. |
artikel |
21 |
Novel variant form of t(11;22)(q23;q13)/MLL-EP300 fusion transcript in the evolution of an acute myeloid leukemia with myelodysplasia-related changes
|
Duhoux, Francois P. |
|
2011 |
35 |
3 |
p. e18-e20 nvt p. |
artikel |
22 |
Race and intensity of post-remission therapy in acute myeloid leukemia
|
Brady, Anna K. |
|
2011 |
35 |
3 |
p. 346-350 5 p. |
artikel |
23 |
Rapid reversal of quadraparesis in chronic eosinophilic leukaemia expressing the FIP1L1-PDGFRA transcript after therapy with imatinib
|
Hus, Marek |
|
2011 |
35 |
3 |
p. e15-e17 nvt p. |
artikel |
24 |
Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease
|
D’Arena, Giovanni |
|
2011 |
35 |
3 |
p. 363-368 6 p. |
artikel |
25 |
Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers
|
Dubovsky, Jason A. |
|
2011 |
35 |
3 |
p. 394-404 11 p. |
artikel |
26 |
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens
|
Price, Samantha L. |
|
2011 |
35 |
3 |
p. 301-304 4 p. |
artikel |
27 |
Salvaging AML with CLAG: Novel option, or more of the same?
|
Wei, Andrew |
|
2011 |
35 |
3 |
p. 297-298 2 p. |
artikel |
28 |
Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial
|
Beksac, Meral |
|
2011 |
35 |
3 |
p. 340-345 6 p. |
artikel |
29 |
Significance of AF4-MLL reciprocal fusion in t(4;11) leukemias?
|
Sanders, Daniel S. |
|
2011 |
35 |
3 |
p. 299-300 2 p. |
artikel |
30 |
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation
|
Sorà, Federica |
|
2011 |
35 |
3 |
p. 422-423 2 p. |
artikel |
31 |
The expansion of T-cells and hematopoietic progenitors as a result of overexpression of the lymphoblastic leukemia gene, Lyl1 can support leukemia formation
|
Lukov, Georgi L. |
|
2011 |
35 |
3 |
p. 405-412 8 p. |
artikel |
32 |
The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
|
Sanchez, Eric |
|
2011 |
35 |
3 |
p. 373-379 7 p. |
artikel |
33 |
The Myelodysplastic Syndromes (MDS) Foundation: A retrospective analysis of a nonprofit foundation
|
Bennett, John M. |
|
2011 |
35 |
3 |
p. 283-285 3 p. |
artikel |
34 |
The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients
|
Terpos, Evangelos |
|
2011 |
35 |
3 |
p. 295-296 2 p. |
artikel |
35 |
The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia
|
Marcolino, Milena Soriano |
|
2011 |
35 |
3 |
p. 317-322 6 p. |
artikel |
36 |
t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL
|
Kumar, Ashish R. |
|
2011 |
35 |
3 |
p. 305-309 5 p. |
artikel |